Naoki Okamura
Profile
Performance in office
Tenure
Tenure
Background
He joined the company in April 1986 and became an Executive Officer in June 2016. He became Executive Vice President in April 2019 and Representative Director and Executive Vice President in June of that year, and took office as Representative Director and President in April 2023. It was 37 years from joining to the presidency and seven years from becoming an Executive Officer. He joined in April 1986, the same as his predecessor Kenji Yasukawa, and had been with the company since 19 years before Astellas Pharma was formed through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical in April 2005.
Selection
In April 2023 he became Representative Director and President, succeeding Kenji Yasukawa. In the fiscal year ended March 2023, the year before he took office, operating income was ¥133.0 billion and net income ¥98.7 billion on consolidated revenue of ¥1,518.6 billion, with net income down ¥25.3 billion from ¥124.0 billion the year before. Employees had also fallen over five years, from 16,617 in FY ended March 2018 to 14,484. The promotion came three years and ten months after he became Representative Director and Executive Vice President.
Initiatives
In the fiscal year ended March 2024, his first year, consolidated revenue grew by ¥85.0 billion to ¥1,603.6 billion, while operating income fell to ¥25.5 billion and net income to ¥17.0 billion. In FY ended March 2025 revenue was ¥1,912.3 billion, operating income ¥41.0 billion and net income ¥50.7 billion, and in FY ended March 2026 revenue was ¥2,139.2 billion, operating income ¥382.6 billion and net income ¥291.5 billion. Revenue grew by ¥620.6 billion in three years from ¥1,518.6 billion in the year before he took office.
Career
Career
Astellas Pharma
| Date | Position |
|---|---|
| Apr 1986 | Joined |
| Jun 2016 | Executive Officer |
| Apr 2019 | Executive Vice President, Executive Officer |
| Jun 2019 | Representative Director, Executive Vice President |
| Apr 2023 | Representative Director, President |
References 1
References (Japanese primary sources)
- アステラス製薬 有価証券報告書（役員の状況）